Seven RCTs (n=5,249) were included.
Symptomatic VTE (2 studies with clinical assessment of VTE performed independently of knowledge of mandatory objective testing and using a standardised predefined method to diagnose symptomatic venous thromboembolism).
There was no significant difference between treatments in the risk of symptomatic VTE. Frequency was 2.7% with control and 1.1% with treatment (ARR 1.56%, 95% CI: -0.21, 3.30). No statistically significant heterogeneity was detected. The NNT was 64.
Symptomatic PE (5 studies).
There was no significant difference between treatments in the risk of symptomatic PE. Frequency was 0.36% with control and 0% with treatment (ARR 0.36%, 95% CI: -0.30, 1.36). No statistically significant heterogeneity was detected. The NNT was 278.
Fatal PE (7 studies).
There was no significant difference between treatments in the risk of fatal PE. Frequency was 0.09% with control and 0% with treatment (ARR 0.09%, 95% CI: -0.08, 0.27). No statistically significant heterogeneity was detected. The NNT was 1,093.